<DOC>
	<DOC>NCT01076322</DOC>
	<brief_summary>This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Ventolin® MDI in stable asthma patients.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<criteria>1. Male or females outpatients aged ≥ 16 years old with stable mild to moderate persistent asthma; Stability was assessed the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days; 2. Pulmonary function test: Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2agonist before the study or ; Positive result of Bronchoprovocation test (PC20 ≤ 32 mg/ml) before the study. 3. Baseline forced expiratory volume in one second 60% ≤(FEV1)≤ 90% of predicted value on entry of the study; 1. Hypersensitivity to β2agonist or lactose; 2. Hospitalization due to asthma during the previous 3months; 3. Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks; 4. Oral or systemic corticosteroids in the previous 4weeks; 5. Inadequately controlled hyperthyroidism; 6. Severe hepatic or renal or cardiovascular disease as judged by the investigator; 7. Patients receive an investigational drug within 30 days prior to admission to the study; 8. Patients with significant alcohol, drug or medication abuse as judged by the investigator; 9. Females who are pregnant or breastfeeding; (exception: Females of childbearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions).</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>